Observational studyMedicine2026
Global, regional, and national analyses of the burden of pancreatic cancer attributable to high fasting plasma glucose from 1990 to 2021: A longitudinal observational study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
High fasting plasma glucose (HFPG) is the second dominant metabolic risk factor contributing to the global burden of pancreatic cancer (PC). However, detailed investigations into the spatiotemporal patterns of PC burden attributable to HFPG remain limited. This study aims to assess global, regional, and national trends in PC mortality and disability-adjusted life years (DALYs) attributable to HFPG from 1990 to 2021. This longitudinal observational study was based on data from the global burden of disease 2021 study, covering data from 204 countries and territories. We extracted mortality, DALYs, age-standardized mortality rate (ASMR), and age-standardized DALY rate (ASDR) for PC attributable to HFPG. These metrics were stratified by sex, age group, country, and socio-demographic index (SDI). Temporal trends were evaluated using the estimated annual percentage change (EAPC) for ASMR and ASDR between 1990 and 2021. In 2021, an estimated 132,753 (95% uncertainty interval [UI]: 15,077-252,345) deaths and 2,751,644 (95% UI: 315,351-5,201,444) DALYs were attributable to HFPG, accounting for 40.9% and 39.3% of total PC-related deaths and DALYs, respectively. From 1990 to 2021, the number of HFPG-attributable PC deaths and DALYs increased by 234.1% and 209.7%, respectively. Substantial regional and national disparities were observed in the burden of PC attributable to HFPG. The highest ASMR and ASDR were recorded in high-SDI regions. Among global regions, East Asia reported the largest number of HFPG-attributable PC deaths and DALYs. The burden was also disproportionately higher among males and older adults. Notably, both ASMR and ASDR were significantly inversely correlated with EAPC. The global burden of PC attributable to HFPG has risen substantially over the past 3 decades, with marked regional and demographic disparities. These findings underscore the urgent need for glycemic control strategies and nutrition-based public health interventions to reduce HFPG-related cancer burden, particularly among high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.